Global IL-17 Biologics Research Report 2023-2030: A $4.37 Billion Market in 2022 - Advancements in Monoclonal Antibody Engineering Fuel Development of Targeted IL-17 Biologics

Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Global IL-17 Biologics Market (2023 Edition): Analysis By Indication, By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By Country: Market Insights and Forecast (2024-2030)" report has been added to's offering.

The Global IL-17 Biologics Market is expected to generate USD 10.9 Billion by the end of 2030, up from USD 4.37 Billion in 2022. During the forecast period, 2024-2030, Global IL-17 Biologics is expected to expand at a CAGR of 12.3 %.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC) and 9 countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, Australia). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

A favourable growth element for the global IL-17 Biologics market has propelled the increasing prevalence of autoimmune and inflammatory diseases, the effectiveness of these drugs in managing these conditions, and the demand for innovative treatments. The implementation of patient support programs, including financial assistance, educational resources, and access to healthcare professionals, enhanced patient adherence and overall satisfaction with IL-17 biologics. These programs are pivotal in ensuring the success of these treatments.

According to the National Stem Cell Foundation, nearly 4% of the world's population is affected by one of more than 80 different autoimmune diseases. Autoimmune diseases represent the third most common cause of chronic illness in the United States. For unknown reasons, the prevalence of autoimmune diseases is increasing. The use of IL-17 inhibitors in these autoimmune disorders reflects the versatility and potential of this class of biologics in managing various conditions characterized by immune system dysregulation and inflammation.

Advancements in monoclonal antibody engineering have led to the development of highly targeted IL-17 biologics. Techniques like antibody humanization and affinity maturation help create more effective and specific biologics with reduced side effects.

To ensure the long-term safety and efficacy of IL-17 biologics, innovative immunogenicity testing methods have been developed to monitor and manage immune responses to these treatments. These tests play a crucial role in detecting the development of anti-drug antibodies, thereby maintaining treatment effectiveness.

Technological advancements have led to the development of innovative drug delivery systems for IL-17 biologics. For instance, autoinjectors have been created to make self-administration easier for patients. Cosentyx (Secukinumab) is available in a pre-filled syringe or autoinjector, enhancing patient convenience.

The IL-17 biologics market is expanding as these drugs receive regulatory approvals for additional autoimmune disease indications. For instance, Secukinumab was initially approved for treating psoriasis and later received approval for ankylosing spondylitis and psoriatic arthritis, broadening its market potential. The growth in indications increases the patient population eligible for IL-17 biologics.

Key Attributes:

Report AttributeDetails
No. of Pages170
Forecast Period2024 - 2030
Estimated Market Value (USD) in 2024$5.43 Billion
Forecasted Market Value (USD) by 2030$10.92 Billion
Compound Annual Growth Rate12.3%
Regions CoveredGlobal

Scope of the Report

  • Global IL-17 Biologics Market Assessment (2022-2030)
  • Impact Analysis of Macro Economic Factors on Global IL-17 Biologics Market
  • Epidemiology
  • Pipeline development of IL-17 Biologics
  • Global IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
  • Degree of Impact of Covid-19 on IL-17 Biologics Market
  • Global IL-17 Biologics Market Segmentation: By Indication
    • Global IL-17 Biologics Market, By Indication Overview
    • Global IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
    • Global IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
    • Global IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
  • Global IL-17 Biologics Market Segmentation: By Drug
    • Global IL-17 Biologics Market, By Drug Overview
    • Global IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
    • Global IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
    • Global IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
    • Global IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)

Competitive Landscape

  • Companies' Product Positioning
  • Market Share of Leading Companies

Company Profiling

  • Novartis
  • Eli Lilly and Company
  • UCB
  • AstraZeneca PLC

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global IL-17 Biologics Market

Contact Data